©2022 Stanford Medicine
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
Not Recruiting
Trial ID: NCT00855647
Purpose
To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated
radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and
effective in the treatment of low-risk localized prostate cancer.
Official Title
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
Stanford Investigator(s)
James D. Brooks
Keith and Jan Hurlbut Professor
Harcharan Gill
Kathryn Simmons Stamey Professor, Emeritus
Steven Hancock, MD
Professor of Radiation Oncology (Radiation Therapy), Emeritus
Eligibility
Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial
PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores
involved.
- Patients who have had any form of prior curative treatment (surgery, radiotherapy,
cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3
months duration will be allowed.
- Adult men will be considered.
- No life expectancy restrictions will apply.
- Performance Status will not be considered.
- No requirements for organ or marrow function will be made
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:- No prior prostate treatment will be allowed.
- The use of other concurrent Investigational Agents will not be allowed.
- No exclusion requirements due to co-morbid disease or incurrent illness.
- No requirements regarding history of allergic reactions.
- Pregnancy or nursing patients is not applicable (ie. patients are male).
Intervention(s):
procedure: Hypo-fractionated Radiotherapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Gillian McFarlane
6507212034